The Norwegian Radium Hospital Research Foundation and Cancer Research Technology form a strategic alliance to co-develop novel cancer therapeutics and diagnostics
Cancer Research Technology (CRT, a specialist oncology development and commercialisation company), and the Norwegian Radium Hospital Research Foundation (the NRHRF, office of technology transfer and industrial relations for the Norwegian Radium Hospital) announce a strategic alliance to co-develop novel cancer therapeutics and diagnostics.
Within the strategic alliance, CRT and the NRHRF have agreed terms under which they will collaborate on selected projects in the development and commercialisation of new cancer therapies and diagnostics generated by researchers at the Norwegian Radium Hospital.
Co-located with a strong research institute, The Norwegian Radium Hospital provides a focused environment for translating laboratory-based research discoveries into the clinic.
"We are very pleased to have this opportunity to benefit from CRT's experience.
"It is hoped that through our partnership with CRT new and exciting cancer therapies will be advanced towards the clinic" stated Jonas Einarsson, CEO at NRHRH.
"CRT is delighted to form an alliance with the NRHRF as part of our global initiative to partner with world-class academic research organisations" said Keith Blundy, COO at CRT.
"We look forward to combining the expertise in cancer drug development and commercialisation at CRT with the excellent translational research activities in the Norwegian Radium Hospital."
